One cause of EED is enterovirus infection. We found that enterovirus in stool on the day of vaccination was associated with diminished rotavirus IgA vaccine response. 8 It is probable that rotavirus vaccine failure is in part due to a failure of vaccine virus replication resulting from an active gut antiviral immune response. 8 Despite the issue of a less effective response in LMICs, the WHO Strategic Advisory Group of Experts on Immunization has recommended rotavirus vaccination as part of the Expanded Program on Immunization for all regions of the world. This recommendation is in large part This is an Open Access article under the CC BY 4.0 license. wap3g@virginia.edu. We declare no competing interests.
because of the benefit in reduction in child mortality and morbidity from even a partly effective vaccine.
In The Lancet Infectious Diseases, Andrew Clark and colleagues 9 examined all randomised controlled trials of rotavirus vaccination published before April 4, 2018. They classified the trials' settings into low-mortality, medium-mortality, and high-mortality strata, and estimated stratum-specific vaccine efficacy over time from a Bayesian hierarchical Poisson meta-regression model, which accounted for observed study-level characteristics and unmeasured heterogeneity among the studies. Clark and colleagues 9 also converted the cumulative vaccine efficacy to instantaneous vaccine efficacy to account for the potential temporal changes of rotavirus failure risk and tested for waning efficacy over the first year of life. The result was a validation of low rotavirus vaccine efficacy in low-income and highmortality settings for the prevention of severe rotavirus diarrhoea, with only 44% effectiveness (95% credibility interval 27-59) after 12 months compared with 94% (87-98) effective in high-income and low-mortality settings. Vaccine efficacy waned more rapidly in high-mortality settings leading to the important observation that improvements in efficacy need to address both instantaneous and prolonged immunity.
The research questions arising from this Article are centred on how to improve vaccine efficacy. Rotavirus vaccination expansion throughout high-mortality countries should help to meet the SDG goals, and even small improvements in vaccine efficacy will have a measurable effect on infant mortality due to diarrhoeal diseases. Interference from EED and enterovirus suggests that the gut metabolome and microbiome could have a role, and any metabolites found to be associated with vaccine success might hold potential as vaccine adjuvants. Avoidance of interfering enterovirus infection and EED by administering the first dose of the vaccine at birth is another potentially beneficial strategy.
A promising alternative strategy is to move from a live virus oral vaccination to an inactivated vaccine administered intramuscularly or intradermally, either alone or in combination with oral vaccine, as borne out by experience with the poliovirus vaccination. 10 A heat-inactivated parenteral vaccine can induce mucosal immunity in animal models, [11] [12] [13] and a parenteral subunit vaccine has been shown to be safe and efficacious in a clinical trial with infants in South Africa, 14 spurring a phase 1 and 2 trial that is underway. Indeed, the ability to effectively induce mucosal immunity using parenterally administered vaccines with select adjuvants might render the oral rotavirus vaccine unnecessary in the not-toodistant future. 15 
